See below for details of all PrecisionLife news, events and media activity as well as links to Disease Studies, research, and publications.
PrecisionLife identified as leaders in fight against COVID-19 by Barclays Private Bank
Oxford, UK – PrecisionLife has been identified as a leader in the ongoing fight against COVID-19 by Barclays Private…
30/10/20
4D Meets AI partnering conference
Oxford, UK – We’ll be at LSci Nation’s 4D Meets AI partnering conference this week where we’ll be leading…
17/09/20
MedInvest AI, Big Data, Digital Health, and Telemedicine Conference
Oxford, UK – PrecisionLife CEO Dr Steve Gardner will be presenting at MedInvest’s virtual AI, Big Data, and Digital…
10/09/20
Startup Terrace Global Hack 2020
Oxford, UK – We’re supporting the Startup Terrace Global Hack 2020 – one of Taiwan’s truly international startup events…
9/09/20
Type-II Diabetes Complications
We built combinatorial risk scores that predict which type of complications a type-II diabetes patient is likely to experience.
8/01/21
Endometriosis
We stratified patients from UK Biobank and via combinatorial analysis identified 345 protein-coding genes strongly associated with disease risk.
16/03/21
Schizophrenia
We stratified a schizophrenia patient population to identify disease sub-groups and new targets for treatment responsive and resistant groups.
10/12/20
ALS Patient Stratification Analysis
We found 33 novel genes that were strongly associated with ALS and have selected 10 targets of significant interest for drug discovery screening.
9/12/20
Non-T2 (Non-Eosinophilic) Asthma
We revealed clear genetic differences between T2 / non-T2 asthma patients, leading to stratification biomarkers and novel, validated targets for non-T2 asthma.
10/12/20
Sjögren’s Syndrome
Identification of 299 risk-associated genes that are strongly associated with Sjögren’s syndrome.
23/03/21
Simon Beaulah joins PrecisionLife as SVP of Healthcare & Head of US Operations
Oxford, UK – PrecisionLife has appointed Simon Beaulah as SVP of Healthcare and Head of US Operations. Simon’s appointment…
9/09/20
Digital RESI event
Oxford, UK – We’ll be joining startups, technology partners and global investors at digital ‘Redefining Early Stage Investments’ (RESI)…
27/07/20
PrecisionLife CEO speaks to the 20/15 Visioneers Rock Stars podcast
Oxford, UK – PrecisionLife CEO Dr Steve Gardner was a guest on the thoroughly entertaining 20/15 Visioneers podcast last…
17/07/20
PrecisionLife present at One Nucleus’ ON Helix event
Oxford, UK – Find out a little more about PrecisionLife at the digital ON Helix 20 event next week…
14/07/20
Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients
A study using de-identified clinical claims and labs data for US COVID-19 patients. We replicated previous findings around the…
25/02/21
The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization
The SARS-CoV-2 pandemic has challenged researchers at a global scale. The scientific community’s massive response has resulted in a…
26/05/21
AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing and Combination Therapies
Access to huge patient populations with well-characterized datasets, coupled with novel analytical methods, enables the stratification of complex diseases…
26/06/20
PrecisionLife featured in Financial Times
Oxford, UK – PrecisionLife has been featured in a Financial Times article following our discovery of 68 genes associated…
25/06/20